Cite
Difficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval.
MLA
Pascart, Tristan, et al. “Difficult-to-Treat Gout Flares: Eligibility for Interleukin-1 Inhibition in Private Practice Is Uncommon According to Current EMA Approval.” Rheumatology, vol. 58, no. 12, Dec. 2019, pp. 2181–87. EBSCOhost, https://doi.org/10.1093/rheumatology/kez203.
APA
Pascart, T., Norberciak, L., Ea, H.-K., Graf, S., Guggenbuhl, P., & Lioté, F. (2019). Difficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval. Rheumatology, 58(12), 2181–2187. https://doi.org/10.1093/rheumatology/kez203
Chicago
Pascart, Tristan, Laurène Norberciak, Hang-Korng Ea, Sahara Graf, Pascal Guggenbuhl, and Frédéric Lioté. 2019. “Difficult-to-Treat Gout Flares: Eligibility for Interleukin-1 Inhibition in Private Practice Is Uncommon According to Current EMA Approval.” Rheumatology 58 (12): 2181–87. doi:10.1093/rheumatology/kez203.